1. 上海中医药大学附属市中医医院风湿病科,上海,200071
扫 描 看 全 文
陈薇薇, 苏晓, 沈丕安. 沈氏生地芩连土茯苓汤联合沙利度胺治疗白塞病的临床观察[J]. 上海中医药杂志, 2018,52(3):51-54.
CHEN Weiwei, SU Xiao, SHEN Pi. Clinical observation of Shen’s Shengdi Qinlian Tufuling Decoction combined with thalidomide in the treatment of Behcet’s disease[J]. Shanghai Journal of Traditional Chinese Medicine, 2018,52(3):51-54.
陈薇薇, 苏晓, 沈丕安. 沈氏生地芩连土茯苓汤联合沙利度胺治疗白塞病的临床观察[J]. 上海中医药杂志, 2018,52(3):51-54. DOI: 10.16305/j.1007-1334.2018.03.013.
CHEN Weiwei, SU Xiao, SHEN Pi. Clinical observation of Shen’s Shengdi Qinlian Tufuling Decoction combined with thalidomide in the treatment of Behcet’s disease[J]. Shanghai Journal of Traditional Chinese Medicine, 2018,52(3):51-54. DOI: 10.16305/j.1007-1334.2018.03.013.
目的:观察沈氏生地芩连土茯苓汤治疗白塞病的临床疗效。 方法:将68例白塞病患者随机分为治疗组与对照组,每组34例。治疗组予沈氏生地芩连土茯苓汤(连续服用2个月)联合沙利度胺片减量口服(25 mg/d,1个月后停服),对照组予沙利度胺片口服(第1个月50 mg/d,第2个月25 mg/d,连续服用2个月)。两组疗程均为2个月,随访观察至治疗结束后第4个月,观察临床疗效与不良反应发生率,比较主症有效率及复发率、免疫及急性炎症指标的变化情况。 结果:①治疗组、对照组的临床总有效率分别为94.1%、85.3%;组间临床疗效比较,治疗组明显优于对照组(P<0.05)。②疗程结束后比较,两组口腔溃疡、眼炎、关节炎的有效率差异有统计学意义(P<0.05),其余主症有效率差异无统计学意义(P>0.05);随访结束时比较,两组口腔溃疡、皮肤结节性红斑及关节炎的复发率差异有统计学意义,治疗组明显低于对照组(P<0.05)。③治疗前后组内比较,两组ESR、CRP水平差异均有统计学意义(P<0.05),而IgG、C,3,水平差异无统计学意义(P>0.05);组间治疗后比较,ESR、CRP水平差异均有统计学意义,治疗组改善程度明显优于对照组(P<0.05)。 结论:沈氏生地芩连土茯苓汤治疗白塞病,可在减少沙利度胺用量与用药时间的基础上,明显改善患者的临床症状,减少复发率及用药不良反应。
Objective:To observe the clinical efficacy of Shen’s Shengdi Qinlian Tufuling Decoction in the treatment of Behcet’s disease. Methods68 patients with Behcet’s disease were randomly divided into the treatment group and control group,34 cases in each group. The treatment group was treated with Shen’s Shengdi Qinlian Tufuling Decoction(for continuous 2 months)combined with thalidomide tablets(25 mg/day for one month and then withdraw),the control group was treated with thalidomide tablets(50 mg/day in the first month and 25 mg/day in the second month). The treatment course was 2 months in both group, and the patients were followed-up until 4 months after the end of treatment. The clinical efficacy and adverse reactions were observed, the changes on the effective rate and recurrence rate of main symptoms, immune and acute inflammation indexes were compared. Results:①The clinical total effective rates of the treatment group and control group were 94.1% and 85.3% respectively. The clinical efficacy of the treatment group was significantly better than that of the control group (P,<,0.05).②After treatment, there were statistically significant differences on the effective rates of mouth ulcer, ophthalmia and arthritis between the two groups (P ,<,0.05), while there were no statistically significant differences on the effective rates of the other main symptoms (P,>, 0.05). At the end of follow-up,there were statistically significant differences on the recurrence rates of mouth ulcer, erythema nodosum and arthritis between the two groups, and the recurrence rates of the treatment group were significantly lower than those of the control group (P,<,0.05). ③In both groups,there were statistically significant differences on the levels of ESR and CRP between treatment before and after (P,<,0.05), while there were no statistically significant differences on the levels of IgG and C,3, between treatment before and after (P,>, 0.05). After treatment,there were statistically significant differences on the levels of ESR and CRP between the two groups,and the levels in the treatment group were significantly lower than those in the control group (P,<,0.05). Conclusion:Shen’s Shengdi Qinlian Tufuling Decoction in the treatment of Behcet’s disease can significantly improve the clinical symptoms, reduce the recurrence rate and adverse reactions on the basis of reducing the dosage and time of thalidomide.
白塞病贝赫切特综合征狐惑病生地芩连土茯苓汤免疫抑制增效减毒
Behcet’s diseaseBehcet syndromeBehcet’s syndromeShengdi Qinlian Tufuling Decoctionimmunosuppressionenhancing efficacy and reducing toxicity
0
浏览量
214
下载量
0
CSCD
9
CNKI被引量
关联资源
相关文章
相关作者
相关机构